Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report

There are remarkable differences in the diagnostic and therapeutic management of atopic dermatitis practiced by dermatologists and pediatricians in different countries. Therefore, the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology nominated expert teams who were given the task of finding a consensus to serve as a guideline for clinical practice in Europe as well as in North America. The consensus report is part of the PRACTALL initiative, which is endorsed by both academies.

[1]  M. Flaig,et al.  Cathelicidin deficiency predisposes to eczema herpeticum. , 2006, The Journal of allergy and clinical immunology.

[2]  M. Steinhoff,et al.  IL-31: a new link between T cells and pruritus in atopic skin inflammation. , 2006, The Journal of allergy and clinical immunology.

[3]  B. Harder,et al.  IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. , 2006, The Journal of allergy and clinical immunology.

[4]  M. Worm,et al.  Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi‐centre, randomized, dose–response study , 2006, Allergy.

[5]  M. Cork,et al.  Safety and Tolerability of 1% Pimecrolimus Cream Among Infants: Experience With 1133 Patients Treated for Up to 2 Years , 2006, Pediatrics.

[6]  T. Chatila.  Role of regulatory T cells in human diseases. , 2005, The Journal of allergy and clinical immunology.

[7]  R. Foelster-Holst,et al.  Efficacy of Crisis Intervention Treatment with Topical Corticosteroid Prednicarbat with and without Partial Wet-Wrap Dressing in Atopic Dermatitis , 2005, Dermatology.

[8]  T. Chatila,et al.  Allergic dysregulation and hyperimmunoglobulinemia E in Foxp3 mutant mice. , 2005, The Journal of allergy and clinical immunology.

[9]  R. Holle,et al.  Association study of mast cell chymase polymorphisms with atopy , 2005, Allergy.

[10]  K. Turjanmaa.  The role of atopy patch tests in the diagnosis of allergy in atopic dermatitis , 2005, Current opinion in allergy and clinical immunology.

[11]  S. Ziegler,et al.  Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin , 2005, The Journal of experimental medicine.

[12]  A. Kapp,et al.  Immunomodulation and Safety of Topical Calcineurin Inhibitors for the Treatment of Atopic Dermatitis , 2005, Dermatology.

[13]  S. Friedlander,et al.  Etanercept is minimally effective in 2 children with atopic dermatitis. , 2005, Journal of the American Academy of Dermatology.

[14]  W. Vach,et al.  A comparison between criteria for diagnosing atopic eczema in infants , 2005, British Journal of Dermatology.

[15]  N. Klopp,et al.  Association of NOD1 polymorphisms with atopic eczema and related phenotypes. , 2005, The Journal of allergy and clinical immunology.

[16]  K. Sayama,et al.  New mechanisms of skin innate immunity: ASK1‐mediated keratinocyte differentiation regulates the expression of β‐defensins, LL37, and TLR2 , 2005, European journal of immunology.

[17]  S. Nakaike,et al.  Expression of IL-31 gene transcripts in NC/Nga mice with atopic dermatitis. , 2005, European journal of pharmacology.

[18]  W. Hoetzenecker,et al.  Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis. , 2005, The Journal of allergy and clinical immunology.

[19]  H. Renz,et al.  Brain-derived neurotrophic factor is increased in atopic dermatitis and modulates eosinophil functions compared with that seen in nonatopic subjects. , 2005, The Journal of allergy and clinical immunology.

[20]  J. Epplen,et al.  The genetics of atopic dermatitis: recent findings and future options , 2005, Journal of Molecular Medicine.

[21]  P. Schmid‐Grendelmeier,et al.  IgE-mediated and T cell-mediated autoimmunity against manganese superoxide dismutase in atopic dermatitis. , 2005, The Journal of allergy and clinical immunology.

[22]  J. Ring,et al.  Position paper on diagnosis and treatment of atopic dermatitis , 2005, Journal of the European Academy of Dermatology and Venereology : JEADV.

[23]  H. Sampson,et al.  Food allergy – accurately identifying clinical reactivity , 2005, Allergy.

[24]  R. Fimmers,et al.  Single nucleotide polymorphisms of the IL18 gene are associated with atopic eczema. , 2005, The Journal of allergy and clinical immunology.

[25]  C. Wild,et al.  Risk factors for atopic dermatitis in New Zealand children at 3·5 years of age , 2005, The British journal of dermatology.

[26]  B. Niggemann,et al.  The predictive value of specific immunoglobulin E levels in serum for the outcome of oral food challenges , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[27]  G. Schuler,et al.  Infliximab in the treatment of moderate to severe atopic dermatitis. , 2005, Journal of the American Academy of Dermatology.

[28]  T. Schäfer.  [Prevention of atopic eczema. Evidence based guidelines]. , 2005, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[29]  H. Williams,et al.  Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials , 2005, BMJ : British Medical Journal.

[30]  J. Ring,et al.  The prevalence of positive reactions in the atopy patch test with aeroallergens and food allergens in subjects with atopic eczema: a European multicenter study , 2004, Allergy.

[31]  N. Reynolds,et al.  Guidelines for prescribing azathioprine in dermatology , 2004, The British journal of dermatology.

[32]  C. Akdis,et al.  Apoptosis in tissue inflammation and allergic disease. , 2004, Current opinion in immunology.

[33]  P. Hoeger.  Antimicrobial susceptibility of skin‐colonizing S. aureus strains in children with atopic dermatitis , 2004, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[34]  E. Carter,et al.  A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. , 2004, Journal of the American Academy of Dermatology.

[35]  T. Werfel,et al.  Role of food allergy in atopic dermatitis , 2004, Current opinion in allergy and clinical immunology.

[36]  Z. Tran,et al.  Effect of pimecrolimus cream 1% on skin condition and sleep disturbance in children with atopic dermatitis. , 2004, The Journal of allergy and clinical immunology.

[37]  T. Bieber,et al.  Characterization of FcepsilonRI-bearing CD123 blood dendritic cell antigen-2 plasmacytoid dendritic cells in atopic dermatitis. , 2004, The Journal of allergy and clinical immunology.

[38]  L. Schneider,et al.  FOOD ALLERGY FACTORS ASSOCIATED WITH THE DEVELOPMENT OF PEANUT ALLERGY IN CHILDHOOD , 2004 .

[39]  K. Carlsen,et al.  Dietary prevention of allergic diseases in infants and small children , 2004, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[40]  A. Boner,et al.  Environmental prevention in atopic eczema dermatitis syndrome (AEDS) and asthma: avoidance of indoor allergens , 2004, Allergy.

[41]  K. Nékám,et al.  Standardization of food challenges in patients with immediate reactions to foods – position paper from the European Academy of Allergology and Clinical Immunology , 2004, Allergy.

[42]  Scott R. Presnell,et al.  Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice , 2004, Nature Immunology.

[43]  H. Williams,et al.  Genetic association between an AACC insertion in the 3'UTR of the stratum corneum chymotryptic enzyme gene and atopic dermatitis. , 2004, The Journal of investigative dermatology.

[44]  C. Akdis,et al.  Immune Responses in Healthy and Allergic Individuals Are Characterized by a Fine Balance between Allergen-specific T Regulatory 1 and T Helper 2 Cells , 2004, The Journal of experimental medicine.

[45]  H. Simon,et al.  Eosinophils and atopic dermatitis , 2004, Allergy.

[46]  S. Halken,et al.  Prevention of allergic disease in childhood: clinical and epidemiological aspects of primary and secondary allergy prevention , 2004, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[47]  E. Kownatzki,et al.  Corneometric, sebumetric and TEWL measurements following the cleaning of atopic skin with a urea emulsion versus a detergent cleanser , 2004, Contact dermatitis.

[48]  T. Bieber,et al.  FcepsilonRI engagement of Langerhans cell-like dendritic cells and inflammatory dendritic epidermal cell-like dendritic cells induces chemotactic signals and different T-cell phenotypes in vitro. , 2004, The Journal of allergy and clinical immunology.

[49]  H. Wichmann,et al.  Effect of breast-feeding on the development of atopic dermatitis during the first 3 years of life--results from the GINI-birth cohort study. , 2004, The Journal of pediatrics.

[50]  B. Niggemann,et al.  The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. , 2004, The Journal of allergy and clinical immunology.

[51]  A. Heratizadeh,et al.  Late eczematous reactions to food in children with atopic dermatitis , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[52]  Shinichi Sato,et al.  Expression of fractalkine and its receptor, CX3CR1, in atopic dermatitis: possible contribution to skin inflammation. , 2004, The Journal of allergy and clinical immunology.

[53]  T. Platts-Mills,et al.  T cell epitope-specific defects in the immune response to cat allergen in patients with atopic dermatitis. , 2004, The Journal of investigative dermatology.

[54]  L. Ou,et al.  T regulatory cells in atopic dermatitis and subversion of their activity by superantigens. , 2004, The Journal of allergy and clinical immunology.

[55]  K. Peeters,et al.  Resistance of Staphylococcus aureus to fusidic acid , 2004, International journal of dermatology.

[56]  Donald Y M Leung,et al.  Amendment history : Erratum ( April 2004 ) New insights into atopic dermatitis , 2018 .

[57]  K. Subramanyan.  Role of mild cleansing in the management of patient skin , 2004, Dermatologic therapy.

[58]  M. D. de Bruin‐Weller,et al.  Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell- attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis. , 2004, The Journal of allergy and clinical immunology.

[59]  A. Patrizi,et al.  Clinical effectiveness of a silk fabric in the treatment of atopic dermatitis , 2004, The British journal of dermatology.

[60]  T. Bieber,et al.  Immune mechanisms leading to atopic dermatitis. , 2003, The Journal of allergy and clinical immunology.

[61]  S. Tinkle,et al.  Risks of smallpox vaccination: 200 years after Jenner. , 2003, The Journal of allergy and clinical immunology.

[62]  T. Kupper,et al.  Prevention of leukocyte migration to inflamed skin with a novel fluorosugar modifier of cutaneous lymphocyte-associated antigen. , 2003, The Journal of clinical investigation.

[63]  J. Travers,et al.  Cytokine Milieu of Atopic Dermatitis, as Compared to Psoriasis, Skin Prevents Induction of Innate Immune Response Genes 1 , 2003, The Journal of Immunology.

[64]  D. Umetsu,et al.  Regulatory T cells control the development of allergic disease and asthma. , 2003, The Journal of allergy and clinical immunology.

[65]  D. Leung.  Infection in atopic dermatitis , 2003, Current opinion in pediatrics.

[66]  T. Bieber,et al.  Allergic and nonallergic forms of atopic diseases. , 2003, The Journal of allergy and clinical immunology.

[67]  G. Plewig,et al.  Predisposing factors and clinical features of eczema herpeticum: a retrospective analysis of 100 cases. , 2003, Journal of the American Academy of Dermatology.

[68]  R. Wood,et al.  LONG-TERM TREATMENT WITH CETIRIZINE OF INFANTS WITH ATOPIC DERMATITIS: A MULTI-COUNTRY, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL (THE ETAC TRIAL) OVER 18 MONTHS , 2003, Pediatrics.

[69]  J. Ring,et al.  Silver-Coated Textiles Reduce Staphylococcus aureus Colonization in Patients with Atopic Eczema , 2003, Dermatology.

[70]  C. Bindslev‐Jensen,et al.  Threshold levels in food challenge and specific IgE in patients with egg allergy: is there a relationship? , 2003, The Journal of allergy and clinical immunology.

[71]  T. Bieber,et al.  Allergic hyperreactivity to microbial components: a trigger factor of "intrinsic" atopic dermatitis? , 2003, The Journal of allergy and clinical immunology.

[72]  U. Jappe,et al.  Frequency of sensitization to antimicrobials in patients with atopic eczema compared with nonatopic individuals: analysis of multicentre surveillance data, 1995–1999 , 2003, The British journal of dermatology.

[73]  R. Damstra,et al.  Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study , 2003, BMJ : British Medical Journal.

[74]  A. Nikkels,et al.  Framing the Future of Antifungals in Atopic Dermatitis , 2003, Dermatology.

[75]  C. Akdis,et al.  T helper (Th) 2 predominance in atopic diseases is due to preferential apoptosis of circulating memory/effector Th1 cells , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[76]  J. Cove,et al.  Short‐term effects of topical fusidic acid or mupirocin on the prevalence of fusidic acid resistant (FusR) Staphylococcus aureus in atopic eczema , 2003, British Journal of Dermatology.

[77]  Donald Rudikoff,et al.  The treatment of atopic dermatitis with systemic immunosuppressive agents. , 2003, Clinics in dermatology.

[78]  J. Saurat,et al.  International Consensus Conference on Atopic Dermatitis II (ICCAD II * ): clinical update and current treatment strategies , 2003, The British journal of dermatology.

[79]  Q. Hamid,et al.  Polarized in vivo expression of IL-11 and IL-17 between acute and chronic skin lesions. , 2003, The Journal of allergy and clinical immunology.

[80]  H. Hönigsmann,et al.  Comparison of epidermal hydration and skin surface lipids in healthy individuals and in patients with atopic dermatitis. , 2003, Journal of the American Academy of Dermatology.

[81]  H. Wichmann,et al.  The effect of hydrolyzed cow's milk formula for allergy prevention in the first year of life: the German Infant Nutritional Intervention Study, a randomized double-blind trial. , 2003, The Journal of allergy and clinical immunology.

[82]  Tomas Ganz,et al.  Endogenous antimicrobial peptides and skin infections in atopic dermatitis. , 2002, The New England journal of medicine.

[83]  J. Berth-Jones,et al.  Azathioprine in severe adult atopic dermatitis: a double‐blind, placebo‐controlled, crossover trial , 2002, The British journal of dermatology.

[84]  G. Imokawa,et al.  Decreased levels of sphingosine, a natural antimicrobial agent, may be associated with vulnerability of the stratum corneum from patients with atopic dermatitis to colonization by Staphylococcus aureus. , 2002, The Journal of investigative dermatology.

[85]  F. Wojnarowska,et al.  Guidelines for the management of bullous pemphigoid , 2002, The British journal of dermatology.

[86]  T. Makino,et al.  Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis , 2002 .

[87]  S. Häussler,et al.  Staphylococcus aureus: colonizing features and influence of an antibacterial treatment in adults with atopic dermatitis , 2002, The British journal of dermatology.

[88]  I. Kockum,et al.  Susceptibility loci for atopic dermatitis on chromosomes 3, 13, 15, 17 and 18 in a Swedish population. , 2002, Human molecular genetics.

[89]  M. Boguniewicz,et al.  Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. , 2002, Journal of the American Academy of Dermatology.

[90]  H. Williams,et al.  Randomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild or moderate atopic eczema , 2002, BMJ : British Medical Journal.

[91]  A. Scheynius,et al.  Atopic Eczema/Dermatitis Syndrome and Malassezia , 2002, International Archives of Allergy and Immunology.

[92]  M. Gdalevich,et al.  Does breastfeeding protect against allergic rhinitis during childhood? A meta‐analysis of prospective studies , 2002, Acta paediatrica.

[93]  D. Chinn,et al.  Randomized controlled trial of a single dermatology nurse consultation in primary care on the quality of life of children with atopic eczema. , 2002, The British journal of dermatology.

[94]  C. Akdis,et al.  Targeting keratinocyte apoptosis in the treatment of atopic dermatitis and allergic contact dermatitis. , 2001, The Journal of allergy and clinical immunology.

[95]  T. Werfel,et al.  Bacterial infections and atopic dermatitis , 2001, Allergy.

[96]  C. Akdis,et al.  The differential fate of cadherins during T-cell-induced keratinocyte apoptosis leads to spongiosis in eczematous dermatitis. , 2001, The Journal of investigative dermatology.

[97]  Luting Xu,et al.  Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis. , 2001, The Journal of investigative dermatology.

[98]  C. Akdis,et al.  Epidemiology, clinical features, and immunology of the “intrinsic” (non‐IgE‐mediated) type of atopic dermatitis (constitutional dermatitis) , 2001, Allergy.

[99]  N. Reynolds,et al.  Azathioprine for atopic dermatitis , 2001, Clinical and experimental dermatology.

[100]  B. Diffey,et al.  Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial , 2001, The Lancet.

[101]  A. Fischer,et al.  Treatment of the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) by allogeneic bone marrow transplantation. , 2001, The New England journal of medicine.

[102]  O. Kortekangas-Savolainen,et al.  Systemic ketoconazole is an effective treatment of atopic dermatitis with IgE‐mediated hypersensitivity to yeasts , 2001, Allergy.

[103]  A. Giannetti,et al.  Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines. , 2001, The Journal of allergy and clinical immunology.

[104]  H. Sampson.  Utility of food-specific IgE concentrations in predicting symptomatic food allergy. , 2001, The Journal of allergy and clinical immunology.

[105]  E. Novembre,et al.  Natural history of “intrinsic” atopic dermatitis , 2001, Allergy.

[106]  G. Abecasis,et al.  Genetic linkage of childhood atopic dermatitis to psoriasis susceptibility loci , 2001, Nature Genetics.

[107]  A. Knulst,et al.  SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis , 2001, The British journal of dermatology.

[108]  J. Harper,et al.  First experience of topical SDZ ASM 981 in children with atopic dermatitis , 2001, The British journal of dermatology.

[109]  J. Ortonne,et al.  The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double‐blind controlled study , 2001, The British journal of dermatology.

[110]  D. Leung,et al.  Tacrolimus (FK506): new treatment approach in superantigen-associated diseases like atopic dermatitis? , 2001, The Journal of allergy and clinical immunology.

[111]  J. Bartosik,et al.  Systemic ketoconazole for yeast allergic patients with atopic dermatitis , 2001, Journal of the European Academy of Dermatology and Venereology : JEADV.

[112]  T. Wienker,et al.  A major susceptibility locus for atopic dermatitis maps to chromosome 3q21 , 2000, Nature Genetics.

[113]  U. Wahn,et al.  The Impact of Childhood Atopic Dermatitis on Quality of Life of the Family , 2000, Dermatology and Psychosomatics / Dermatologie und Psychosomatik.

[114]  S. Salminen,et al.  Probiotics in the management of atopic eczema , 2000, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[115]  S. Halken,et al.  Comparison of a partially hydrolyzed infant formula with two extensively hydrolyzed formulas for allergy prevention:A prospective, randomized study , 2000, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[116]  J. Ravenscroft,et al.  Observations on high levels of fusidic acid resistant Staphylococcus aureus in Harrogate, North Yorkshire, UK , 2000, Clinical and experimental dermatology.

[117]  S. Muro,et al.  Evidence for increased expression of eotaxin and monocyte chemotactic protein-4 in atopic dermatitis. , 2000, The Journal of allergy and clinical immunology.

[118]  D. Gustafsson,et al.  Development of allergies and asthma in infants and young children with atopic dermatitis – a prospective follow‐up to 7 years of age , 2000, Allergy.

[119]  R. Valenta,et al.  Autoallergy: a pathogenetic factor in atopic dermatitis? , 2000, Current problems in dermatology.

[120]  J. Ring,et al.  Long-term efficacy of medium-dose UVA1 phototherapy in atopic dermatitis. , 2000, Journal of the American Academy of Dermatology.

[121]  T. Platts-Mills,et al.  Use of specific IgE in assessing the relevance of fungal and dust mite allergens to atopic dermatitis: a comparison with asthmatic and nonasthmatic control subjects. , 1999, The Journal of allergy and clinical immunology.

[122]  P. Klein,et al.  An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. , 1999, Archives of dermatology.

[123]  M. Wjst,et al.  Association between severity of atopic eczema and degree of sensitization to aeroallergens in schoolchildren. , 1999, The Journal of allergy and clinical immunology.

[124]  D. van der Meer,et al.  The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate , 1999, The British journal of dermatology.

[125]  J. Faergemann.  Pityrosporum species as a cause of allergy and infection , 1999, Allergy.

[126]  R. Geha,et al.  Roles of TH1 and TH2 cytokines in a murine model of allergic dermatitis. , 1999, The Journal of clinical investigation.

[127]  P. Hufnagl,et al.  Isolation of cDNA clones coding for IgE autoantigens with serum IgE from atopic dermatitis patients , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[128]  Williams,et al.  The natural history of childhood eczema: observations from the British 1958 birth cohort study , 1998, The British journal of dermatology.

[129]  L. Patel,et al.  Side to side comparison of topical treatment in atopic dermatitis , 1998, Archives of disease in childhood.

[130]  T. Ruzicka,et al.  Human eosinophils produce biologically active IL-12: implications for control of T cell responses. , 1998, Journal of immunology.

[131]  Richard Beasley,et al.  Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC , 1998, The Lancet.

[132]  R. Geha,et al.  Epicutaneous sensitization with protein antigen induces localized allergic dermatitis and hyperresponsiveness to methacholine after single exposure to aerosolized antigen in mice. , 1998, The Journal of clinical investigation.

[133]  T. Luger,et al.  High-dose UVA1 therapy for atopic dermatitis: results of a multicenter trial. , 1998, Journal of the American Academy of Dermatology.

[134]  B. Cohen,et al.  Prevalence of IgE-Mediated Food Allergy Among Children With Atopic Dermatitis , 1998, Pediatrics.

[135]  B. Wedi,et al.  Delayed eosinophil programmed cell death in vitro: a common feature of inhalant allergy and extrinsic and intrinsic atopic dermatitis. , 1997, The Journal of allergy and clinical immunology.

[136]  A. Kemp,et al.  Topical triclosan treatment of atopic dermatitis. , 1997, The Journal of allergy and clinical immunology.

[137]  D. Gawkrodger,et al.  Azathioprine in dermatology: a survey of current practice in the U.K. , 1997, The British journal of dermatology.

[138]  J. English,et al.  Long‐term efficacy and safety of cyclosporin in severe adult atopic dermatitis , 1997, The British journal of dermatology.

[139]  J. English,et al.  Retrospective review of the use of azathioprine in severe atopic dermatitis. , 1996, Journal of the American Academy of Dermatology.

[140]  I. Zaki,et al.  Treatment of severe atopic dermatitis in childhood with cyclosporin , 1996, The British journal of dermatology.

[141]  A. Finlay,et al.  Cyclosporine in severe childhood atopic dermatitis: a multicenter study. , 1996, Journal of the American Academy of Dermatology.

[142]  I. Strickland,et al.  Double-blind controlled trial of effect of housedust-mite allergen avoidance on atopic dermatitis , 1996, The Lancet.

[143]  S. Seidenari,et al.  Objective assessment of the skin of children affected by atopic dermatitis: a study of pH, capacitance and TEWL in eczematous and clinically uninvolved skin. , 1995, Acta dermato-venereologica.

[144]  A. Anstey,et al.  The role of genetic variation in thiopurine methyltransferase activity and efficacy and/or side effects of azathioprine therapy in dermatologic patients. , 1995, Archives of dermatology.

[145]  H. Williams,et al.  Management of atopic eczema. Joint Workshop of the British Association of Dermatologists and the Research Unit of the Royal College of Physicians of London. , 1995, BMJ.

[146]  M. Kerscher,et al.  In vivo assessment of the atrophogenic potency of mometasone furoate, a newly developed chlorinated potent topical glucocorticoid as compared to other topical glucocorticoids old and new. , 1995, International journal of clinical pharmacology and therapeutics.

[147]  J. Stalder,et al.  Local steroid therapy and bacterial skin flora in atopic dermatitis , 1994, The British journal of dermatology.

[148]  H. Degreef,et al.  Atopic dermatitis: triggering factors. , 1994, Journal of the American Academy of Dermatology.

[149]  H. Sampson,et al.  Presence of IgE antibodies to staphylococcal exotoxins on the skin of patients with atopic dermatitis. Evidence for a new group of allergens. , 1993, The Journal of clinical investigation.

[150]  A. Kapp,et al.  The role of eosinophils in the pathogenesis of atopic dermatitis ‐ eosinophil granule proteins as markers of disease activity , 1993, Allergy.

[151]  M. Kerscher,et al.  Topical glucocorticoids with improved benefit/risk ratio: do they exist? , 1992, Journal of the American Academy of Dermatology.

[152]  E. Nilsson,et al.  Topical corticosteroids and Staphylococcus aureus in atopic dermatitis. , 1992, Journal of the American Academy of Dermatology.

[153]  A. Y. Finlay,et al.  Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis , 1991, The Lancet.

[154]  G. Swanbeck,et al.  Parental education in the treatment of childhood atopic eczema. , 1990, Acta dermato-venereologica.

[155]  R. Bergström,et al.  The antipruritic effect of a sedative and a non‐sedative antihistamine in atopic dermatitis , 1990, The British journal of dermatology.

[156]  Jose Mc Skimming,et al.  A PILOT STUDY OF A SUPPORT GROUP FOR PARENTS OF CHILDREN WITH ECZEMA , 1984, The Australasian journal of dermatology.

[157]  M. Chapman,et al.  The role of dust mite allergens in atopic dermatitis , 1983, Clinical and experimental dermatology.

[158]  M. Chapman,et al.  BASOPHILS IN ALLERGEN-INDUCED PATCH TEST SITES IN ATOPIC DERMATITIS , 1982, The Lancet.

[159]  J. Leyden,et al.  The case for steroid—antibiotic combinations , 1977, The British journal of dermatology.

[160]  P. Schmid‐Grendelmeier,et al.  The role of sensitization to Malassezia sympodialis in atopic eczema. , 2006, Chemical immunology and allergy.

[161]  T. Werfel,et al.  Safety and Efficacy of Topical Calcineurin Inhibitors in the Treatment of Childhood Atopic Dermatitis , 2005, American journal of clinical dermatology.

[162]  D. Margolis,et al.  Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association "Administrative Regulations for Evidence-Based Clinical Practice Guidelines". , 2004, Journal of the American Academy of Dermatology.

[163]  R. Dahl,et al.  Atopic dermatitis -- a total genome-scan for susceptibility genes. , 2004, Acta dermato-venereologica.

[164]  F. Mastrandrea.  The Potential Role of Allergen-Specific Sublingual Immunotherapy in Atopic Dermatitis , 2004, American journal of clinical dermatology.

[165]  H. Maibach,et al.  Stratum corneum pH in atopic dermatitis: impact on skin barrier function and colonization with Staphylococcus Aureus. , 2004, American journal of clinical dermatology.

[166]  越後 岳士.  Expression of fractalkine and its receptor, CX3CR1, in atopic dermatitis : possible contribution to skin inflammation , 2004 .

[167]  U. Darsow,et al.  Clinical and immunologic reactivity to aeroallergens in "intrinsic" atopic dermatitis patients. , 2003, The Journal of allergy and clinical immunology.

[168]  C. Akdis,et al.  A second step of chemotaxis after transendothelial migration: keratinocytes undergoing apoptosis release IFN-gamma-inducible protein 10, monokine induced by IFN-gamma, and IFN-gamma-inducible alpha-chemoattractant for T cell chemotaxis toward epidermis in atopic dermatitis. , 2003, Journal of Immunology.

[169]  M. Lóden.  Role of Topical Emollients and Moisturizers in the Treatment of Dry Skin Barrier Disorders , 2003, American journal of clinical dermatology.

[170]  T. Bieber,et al.  Evidence for a differential expression of the FcepsilonRIgamma chain in dendritic cells of atopic and nonatopic donors. , 2003, The Journal of clinical investigation.

[171]  J. Lübbe.  Secondary Infections in Patients with Atopic Dermatitis , 2003, American journal of clinical dermatology.

[172]  G. Hartmann,et al.  Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. , 2002, The Journal of investigative dermatology.

[173]  T. Werfel,et al.  Levels of circulating CD8(+) T lymphocytes, natural killer cells, and eosinophils increase upon acute psychosocial stress in patients with atopic dermatitis. , 2001, The Journal of allergy and clinical immunology.

[174]  T. Bieber,et al.  IgE receptors. , 2001, Current opinion in immunology.

[175]  C. Akdis,et al.  T cell-mediated Fas-induced keratinocyte apoptosis plays a key pathogenetic role in eczematous dermatitis. , 2000, The Journal of clinical investigation.

[176]  A. Wolkerstorfer,et al.  Treatment of erythrodermic atopic dermatitis with “wet-wrap” fluticasone propionate 0.05% cream/emollient 1:1 dressings , 1999 .

[177]  J. Warner.  Early treatment of the atopic child. , 1997, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[178]  Q. Hamid,et al.  Granulocyte macrophage colony-stimulating factor contributes to enhanced monocyte survival in chronic atopic dermatitis. , 1995, The Journal of clinical investigation.

[179]  S. Powell,et al.  'Wet-wrap' dressings for the treatment of atopic eczema in the community , 1994 .

[180]  D. Gawkrodger,et al.  The prevalence of childhood atopic eczema in a general population. , 1994, Journal of the American Academy of Dermatology.

[181]  M. Preece,et al.  The treatment of difficult atopic dermatitis in childhood with oral beclomethasone dipropionate. , 1992, Acta dermato-venereologica. Supplementum.

[182]  R. Geha,et al.  Characterization of the mononuclear cell infiltrate in atopic dermatitis using monoclonal antibodies. , 1983, The Journal of allergy and clinical immunology.

[183]  I I Lelis,et al.  [Atopic dermatitis]. , 1980, Vestnik dermatologii i venerologii.